Scientific reports
Serum interferon-λ3 as a short-term biomarker of disease control in anti-MDA5-positive dermatomyositis-associated ILD.
Yoshihiro Kitahara, Tomoyuki Fujisawa, Atsuki Fukada, Keigo Koda, Taisuke Akamatsu, Masaki Ikeda, Masato Fujii, Mitsuru Niwa, Yusuke Kaida, Hiroyuki Matsuda, Koshi Yokomura, Naoki Koshimizu, Mikio Toyoshima, Shiro Imokawa, Dai Hashimoto
Published: 202610.1038/s41598-026-37104-x
Abstract
This study aimed to assess the clinical utility of serum interferon-lambda 3 (IFN-λ3) as a sequential biomarker for treatment response and disease control in patients with anti-melanoma differentiation-associated gene 5 (MDA5) antibody-positive derma…
Preview only. Read the full abstract at the source